TORONTO
GENERAL HOSPITAL/ ST. MICHAEL'S HOSPITAL DEPARTMENTS
OF PHARMACY SERVICES HIV
SPECIALTY RESIDENCY PROGRAM
HIV AMBULATORY CARE ROTATION - TORONTO GENERAL HOSPITAL SITE:
Immunodeficiency Clinic, Toronto General Hospital
Location:
13North, room 1300;
- the clinic serves over 1400 patients a year, making it the largest outpatient clinic in Ontario, and one of the largest in Canada
- medical staff comprised of HIV/infectious disease specialists and internists with expertise in HIV
- a comprehensive interdisciplinary approach (includes medicine, nursing, pharmacy, social work, nutrition, and psychology) is utilised to provide patient care
- also a leading centre for HIV research; clinic is involved with over 35 ongoing trials, including phase II/III, pharmacokinetics, open-label/expanded access, and epidemiologic studies
DURATION OF ROTATION:
PRECEPTOR:
Alice Tseng, Pharm.D.
Immunodeficiency Clinic
Toronto General Hospital
Tel:
(416) 340-4800, ext. 8763 Fax:
(416) 340-4890
e-mail: Alice.Tseng@uhn.on.ca
Pager: (416)
739-2347
GOALS:
1. To acquire an appropriate degree of knowledge of various HIV-related topics in order to adequately and efficiently identify, resolve, and prevent drug-related problems in the HIV-infected
ambulatory population.
2. To allow the resident to develop critical thinking skills, in order to analyze and integrate pertinent disease, drug and patient data and concepts for the purposes of being
able to provide effective pharmaceutical care.
3. To develop an understanding and appreciation of the clinical role of the pharmacist in a specialty outpatient care setting.
OBJECTIVES:
1. The resident will acquire knowledge of the principles, strategies, and protocols for treating HIV infection and opportunistic infections (see appendix 1).
2. The resident will acquire an
understanding and appreciation of drug-related issues commonly encountered in the management of patients infected with HIV.
3. The resident will be able to develop strategies to manage patients with
evolving medical conditions and complex drug-related issues on an ongoing basis.
Terminal Competencies
At the end of this rotation, the resident will be able to:
1.
Discuss principles and current
recommendations for both the
management of HIV infection as
well as treatment and prevention
of various opportunistic infections:
a)
basic pathophysiology of the
disease state affecting the
patient with respect to pathogenesis,
epidemiology, risk factors, clinical
presentation, laboratory indices
affected, diagnostic criteria;
b) approach to therapeutic management,
pharmacologic and non-pharmacologic;
c)
available pharmacologic agents
and factors affecting the selection
of an optimal treatment regimen;
d)
pertinent monitoring parameters,
including frequency, acceptable
endpoints and duration of monitoring,
for both efficacy and toxicity;
e)
pharmacological issues pertinent
or of interest to pharmacists
2.
Discuss the advantages and disadvantages,
indications and contraindications
of the various antiretroviral agents
(Appendix 2) with respect to:
a) efficacy;
b)
resistance patterns;
c)
dosage regimen;
d)
bioavailability of oral dosage
forms;
e)
toxicity;
f)
convenience;
g)
availability, including Formulary
status;
h) drug interactions;
i)
cost
3. To be able to anticipate and prevent,
and/or identify and resolve individual
patient's drug-related problems:a)
To be able to collect relevant
drug, disease, and patient information
in an effective and concise manner. This
may be done via: chart
review, patient interview, utilizing
resources (including standard
textbooks, published medical
literature, conference abstracts,
unpublished data from manufacturers
and investigators, and reliable
Internet sites), and communication
with other health professionals
(including community/hospital
pharmacists, family physicians,
nurses, etc.).
b) To analyze and integrate pertinent
data in order to identify actual
and potential drug-related issues
for individual patients, in an
accurate and efficient manner.
c) To be able to prioritize drug-related
issues through discussions with
the patient and health care team.
d)
To be able to develop and provide
appropriate recommendations on
the management or prevention
of each drug-related problem
in a timely manner. The
resident should be able to provide
rationale for his/her pharmacy
care plans, and be able to modify
recommendations based on individual
patient factors.
e)
To communicate care plans, recommendations,
and drug-related information
effectively with patients, family
members, and members of the health
care team. This may be
done in person, over the telephone,
chart documentation, or through
written consult letters.
f)
To effectively provide follow-up
care by determining desired therapeutic
outcomes and developing monitoring
plans that incorporate efficacy
and toxicity endpoints.
g)
To develop an awareness of how
various psycho-social, ethical,
cultural, and economic factors
are involved in the management
of HIV-infected individuals. 4.
To be able to provide appropriate,
timely and concise drug information
to the team upon request. This
may be in the form of answering brief
queries, researching in-depth issues,
and/or making informal or formal
presentations.
a) Identify the issues that need
to be researched in order to
provide comprehensive, complete
drug information.
b) Independently utilize the available
drug information resources to
research the pertinent literature.
c)
Use critical appraisal skills
to assess the quality, clinical
significance, and relevance of
information in the area of HIV/infectious
diseases.
d)
Is able to synthesize pertinent
material and prepare a concise
presentation.
e)
Effectively and efficiently present
the information to the team.
f)
Answer questions with appropriate
terminology, conclusions, recommendations
and references.
5. To be able to function as a mature,
responsible, professional member
of the health care team.a)
To be able to identify and
prioritize learning objectives,
and to continually expand
and modify these objectives
as required throughout the
rotation.
b)
Is able to gather and process
information in a self-directed
manner, by utilizing available
resources and identifying when
assistance or feedback is required
from the preceptor.
c)
Has the ability to problem-solve
in a systematic, logical manner.
d)
Is able to respond positively
to constructive feedback. Appendix
1. Therapeutic Topics
HIV (general) epidemiology
- pathogenesis
- surrogate markers
- natural history
- spectrum of disease
- principles of therapy
- prevention issues
Opportunistic Infections (OIs) in HIV epidemiology, presentation, treatment, prophylaxis:
- Pneumocystis carinii pneumonia (PCP)
- Toxoplasmosis
- cryptococcal meningitis
- mycobacterial infections (tuberculosis and M.avium complex)
- cytomegalovirus (CMV)
- candidiasis
- intestinal parasites
- impact of HAART on opportunistic
infections (presentation, treatment
duration, need for secondary prophylaxis)
Other AIDS-Associated Conditions lipodystrophy, metabolic complications
- weight loss/cachexia
- diarrhea
- peripheral neuropathy, pain control
- psychiatric illnesses
- AIDS dementia complex (ADC)
Medication-Related Issues in HIV
- drug-disease considerations
- medication adherence
- drug interactions
- management of adverse drug reactions (acute, transient, chronic)
- medication costs/acquisition
- therapeutic drug monitoring
HIV in Specific Patient Populations women, including pregnancy and breastfeeding issues
- injection drug users (IDUs)
- health care workers (via occupational exposure)
- new immigrants
Appendix
2: Antiretroviral
Therapy
1. Reverse Transcriptase Inhibitors
a) zidovudine (AZT), didanosine
(ddI), zalcitabine (ddC),
lamivudine (3TC), stavudine
(d4T), abacavir,
tenofovir, emtricitabine
(FTC)
2. Non-Nucleoside Reverse
Transcriptase Inhibitors
3. Protease Inhibitors
a) amprenavir, atazanavir,
fosamprenavir,
indinavir, lopinavir,
nelfinavir,
saquinavir,
ritonavir, tipranavir
Revised
2006
|